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Abstract
Background: Abacavir has been associated with an increased risk of acute myocardial infarction, but the
pathogenic mechanisms remain unknown. We evaluated longitudinal changes in pro-atherosclerotic biomarkers in
patients initiating abacavir or tenofovir.
Methods: Consecutive patients initiating antiretroviral therapy (ART) with abacavir/lamivudine or tenofovir/
emtricitabine were included. Plasma levels of high sensitivity C reactive protein (hsCRP), interleukin-6 (IL-6),
intercellular adhesion molecule-1, vascular cell adhesion molecule-1 (sVCAM-1) and plasminogen activator inhibitor-
1 (PAI-1) were measured at baseline and at different time points throughout 48 weeks. Comparisons were adjusted
for age, sex, ART status at inclusion, viral load, lipodystrophy, Framingham score and hepatitis C virus co-infection
status.
Results: 50 patients were analyzed, 28 initiating abacavir and 22 tenofovir. The endothelial biomarker sVCAM-1
declined significantly in both treatment groups. hsCRP tended to increase soon after starting therapy with abacavir,
a trend that was not seen in those initiating tenofovir. IL-6 significantly increased only at week 24 from baseline in
patients on abacavir (+225%, p < 0.01) although the differences were not significant between groups. The
procoagulant biomarker PAI-1 plasma levels increased from baseline at week 12 (+57%; p = 0.017), week 24 (+72%;
p = 0.008), and week 48 (+149%; p < 0.001) in patients on tenofovir, but differences between groups were not
statistically significant.
Conclusion: Changes in biomarkers of inflammation, coagulation, and endothelial function are not different in
viremic patients starting ART with abacavir/lamivudine or tenofovir/emtricitabine. These changes occur in the early
phases of treatment and include anti- and pro-atherosclerotic effects with both drugs.
Background
Current or recent use of abacavir has been associated
with an increased risk of developing acute myocardial
infarction (MI) in the D:A:D cohort study [1] and in
observational data derived from the SMART trial [2].
The excess risk of cardiovascular disease (CVD) did not
seem to be explained by the underlying cardiovascular
risk factors and was no longer present in patients who
had stopped abacavir for more than 6 months [1], sug-
gesting an acute or subacute direct effect of the drug.
To date, the mechanisms leading to this hypothetical
higher CVD risk remain unknown.
In the SMART study, two inflammatory biomarkers,
high sensitivity C-reactive protein (hsCRP) and interleu-
kin (IL)-6, were found to be higher among patients who
were receiving abacavir than in those using other
nucleoside reverse transcriptase inhibitors (NRTIs), sug-
gesting a pro-inflammatory mechanism of the drug [2].
However, the cross-sectional nature of one isolated mea-
surement precluded establishing a direct causal effect.
Conversely, longitudinal data from two randomized
trials comparing antiretroviral regimens including abaca-
vir versus tenofovir in naïve [3] and in treated and viro-
logically suppressed [4] patients revealed a decrease or a
lack of changes in the levels of CVD biomarkers.
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switching to abacavir [5] also showed no significant
changes in inflamatory biomarkers. It has been hypothe-
sized that, in patients initiating antiretroviral therapy
(ART), the benefits of controlling viral replication might
surpass the proatherosclerotic effects of abacavir [6].
Unfortunately, the time between baseline and following
samples collection in the mentioned studies was one
year or higher, thus preventing from identifying the
early effects of the drug. Because the highest risk might
occur during the early phases after initiating the drug
[1], investigations addressing the mechanisms implicated
should also explore the early period after exposure.
To investigate the influence of abacavir on CVD risk,
we evaluated longitudinal changes in a number of
inflammation (hsCRP, IL-6), coagulation (plasminogen
activator inhibitor-1 [PAI-1]) and endothelial function
(intercellular adhesion molecule-1 [sICAM-1] and vas-
cular cell adhesion molecule-1 [sVCAM-1]) biomarkers
in viremic patients initiating a regimen including abaca-
vir/lamivudine or tenofovir/emtricitabine, with special
attention to the early phases of drug exposure.
Methods
Patient selection
Eligible patients were all HIV-infected adults (age, ≥18
years) cared for in the outpatient HIV clinic of a univer-
sity hospital (Hospital General Universitario, Elche,
Spain) from December 2006 through March 2008, initi-
ating a regimen including either abacavir/lamivudine or
tenofovir/emtricitabine. Candidates for inclusion were
ART naïve patients, and patients previously exposed to
ART who had discontinued treatment for at least 6
months. Patients who had ever received either abacavir
or tenofovir were excluded. For the purpose of this
study, only patients who remained on the same ART
regimen during follow-up were included in the analyses.
HLA-B*5701 screening was not performed, and those
patients in whom hypersensitivity reaction to abacavir
had been suspected were not included in the study. The
study was approved by the Hospital General Universi-
tario de Elche Ethics Committee (CEIC), and an
informed consent was obtained from all the patients.
Measurements
Patients were evaluated at baseline and at weeks 4, 12,
24 and 48. At each visit, blood samples were obtained
and plasma aliquots stored at -80°C. In January 2009 all
frozen samples were defrosted and simultaneously
plasma levels of several biomarkers potentially relevant
to CVD were measured. More precisely, we determined
levels of hsCRP and IL-6 as inflammatory biomarkers;
sICAM-1 and sVCAM-1 as endothelial function mar-
kers; and PAI-1 as procoagulative marker.
Plasma concentrations of IL-6, sVCAM-1, sICAM-1
and PAI-1 were measured using commercially available
ELISA kits (Quantikine, R&D Systems Europe Ltd, UK),
and hsCRP with the IMMULITE 2000 Analyzer (Sie-
mens, Los Angeles, USA) as previously described [7].
Intra- and inter- assay variability of these tests were
(CV, minimum-maximum %]): IL-6, 5.9-7.4 and 6.5-9.6;
sVCAM-1, 2.3-3.6 and 5.5-7.8; sICAM-1 3.6-5.2 and
4.4-6.8; PAI-1 4.4-8.0 and 6.1-9.5, hsCRP, 2.8-8.7 and
3.1-8.7.
Statistical Analyses
Differences in baseline characteristics between the two
treatment groups were assessed through the
2 and
Mann-Whitney tests for categorical and continuous
variables, respectively. To assess whether changes in bio-
markers levels at weeks 4, 12, 24 and 48 were signifi-
cantly different from baseline in each treatment group,
and whether those changes were significantly different
between the two treatment groups, we used linear
mixed models including the interaction between treat-
ment group and week of therapy as categorical. Linear
mixed models allowed us to accommodate multiple
measures per person.
Changes in biomarker levels were assessed on the nat-
ural log scale (loge) as the distribution of the biomarkers
was highly skewed. Univariate and multivariate analyses
were performed, with adjustment for age, sex, ART sta-
tus at inclusion (naïve or treatment interruption), viral
load, lipodystrophy, Framingham score and hepatitis C
virus infection. Considering a 0.05 two-sided significance
level, a power of 80% and the sample size of the study, a
difference of means ≥ 40% could be detected between
groups. All statistical analyses were performed by using
Stata software (version 10.0; Stata Corporation, College
Station, Texas).
Results
Of 50 patients who met selection criteria, 28 (56%)
initiated abacavir/lamivudine, and 22 (44%) tenofovir/
emtricitabine. The third component of the regimen was
a non nucleoside reverse transcriptase inhibitor in 68%
and 73%, and a protease inhibitor in 32% and 27%
patients treated with abacavir/lamivudine and tenofovir/
emtricitabine respectively (p = 0.77 for both cases). Of
the 50 patients initially selected, 47, 41, 31 and 21 of
them remained on the same ART regimen at weeks 4,
12, 24 and 48 of follow-up, respectively, and had plasma
samples available for analysis. One patient was of black
race (included in the abacavir group) and all the other
were caucasians.
Thirty two (64%) were ART-naïve patients (19 in the
abacavir/lamivudine group and 13 in the tenofovir/
emtricitabine group, p = 0.56), and 18 (36%) were
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at least 6 months (9 in the abacavir/lamivudine group
and 9 in the tenofovir/emtricitabine group, p = 0.56).
Patients initiating tenofovir/emtricitabine were older
(median [IQR] 40 [35-46] years vs 35 [32-43] years, P =
0.042), and tended to be more frequently male (91% vs
71%, P = 0.088). Other demographic-, HIV- or cardio-
vascular risk-related baseline characteristics were not
different between patients on abacavir/lamivudine or
tenofovir/emtricitabine-based regimens, including pre-
vious time of exposure to ART, hepatitis C virus coin-
fection, Framingham risk score, prevalence of classical
cardiovascular risk factors, and baseline creatinine clear-
ance by Cockroft-Gault. At week 12, 60.0% and 50.6%
patients in abacavir and tenofovir group respectively had
a viral load < 50 c/ml, p = 0.77; week 24, 85.0%
and 66.7%, p = 0.25; and week 48, 94.7% and 89.9%,
p = 0.55. Baseline levels of IL-6 tended to be lower in
patients initiating abacavir/lamivudine (Table 1).
Table 1 shows baseline biomarkers levels and Figure 1
percentages of median changes from baseline of the bio-
markers at the different time points. Changes in the bio-
markers when all the included patients were analyzed
are detailed first. The inflammatory biomarkers showed
an unparallel tendency: hsCRP plasma levels did not
change significantly during the 48-week period. IL-6
increased early after starting therapy (+82%, p = 0.03 at
week 4, +73%, p = 0.06 at week 12 and +154%, p < 0.01
at week 24) and returned to baseline levels at 48-week
visit (+57%, p = 0.18). PAI-1 plasma levels increased sig-
nificantly from week 12 to week 48 (+34%, p = 0.02 at
week 12; +49%, p < 0.01 at week 24, and +71%, p < 0.01
at week 48). The endothelial biomarker sVCAM-1
declined significantly after starting therapy from week 4
Table 1 Baseline characteristics of the patients by treatment group
Initiating abacavir Initiating tenofovir P
a
N 28 22 -
Characteristics at study entry
Male, (%) 71 91 0.088
Age (yrs), median (IQR) 35 (32-43) 40 (35-46) 0.042
Time on ART (yrs)
b, median (IQR) 2.5 (0.75-5.0) 1 (0.55-3.25) 0.463
ART received during the study period
PI based (%) 32 27 0.477
NNRTI based (%) 68 73 0.477
CD4 cell count (cells/mm
3), median (IQR) 260 (152-357) 200 (150-252) 0.072
Lipodystrophy (%) 3.5 13.6 0.308
Prior cardiovascular disease (%) 00 -
Hypertension (%) 7.1 4.5 0.591
Systolic blood pressure (mmHg), median (IQR) 124 (112-130) 119 (111-140) 0.747
Diastolic blood pressure (mmHg), median (IQR) 74 (68-85) 72 (63-83.5) 0.518
Diabetes (%) 00 -
Current smokers (%) 75 81 0.411
Lipid-lowering drugs (%) 3.6% 4.5% 0.691
Total cholesterol (mg/dL), median (IQR) 173 (134-189) 165 (126-201) 0.822
LDL-cholesterol (mg/dL), median (IQR) 99 (84-122) 94 (72-126) 0.747
HDL-cholesterol (mg/dL), median (IQR) 38 (33-46) 42 (30-45) 0.792
Triglycerides (mg/dL), median (IQR) 115 (80-159) 112 (89-179) 0.591
Framingham risk score, median (IQR) 6.0 (1.5-10) 7.5 (3.3-13.3) 0.417
Framingham risk at 10 yrs
c, median (IQR) 2 (1-6) 3.5 (1-13) 0.512
Hepatitis C-virus coinfection (%) 53 45 0.577
eGFR
d (ml/min*1.73m
2), median (IQR) 87.1 (78.3-107.1) 85.8 (67.0-93.2) 0.120
hsCRP levels (mg/L), median (IQR) 1.5 (0.5-3.2) 1.7 (0.6-3.6) 0.845
IL-6 levels (rg/mL), median (IQR) 0.8 (0.3-2.7) 2.7 (0.8-5.6) 0.079
sVCAM-1 (hg/mL), median (IQR) 818 (524-1088) 889 (778-1354) 0.315
sICAM-1 (hg/mL), median (IQR) 499 (370-955) 485 (444,-) 0.840
PAI-1 (hg/mL), median (IQR) 2.6 (1.5-7.1) 2.8 (1.4-4.3) 0.710
aMann-Whitney U test or Chi-square test as appropriate.
bOnly for preteated patients.
cFor coronary heart disease outcomes (myocardial infarction and coronary
death).
dGlomerurar filtration rate estimated by Cockroft-Gault formula. IQR, interquartile range; ART, antiretroviral therapy; PI, protease inhibitor; NNRTI, non
nucleoside reverse transcriptase inhibitor; hsCRP, high sensitivity C reactive protein; IL-6, interleukin-6; sVCAM-1, vascular cell adhesion molecule-1; sICAM,
intercellular adhesion molecule-1; PAI-1, plasminogen activator inhibitor-1.
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week 12; -39%, p < 0.01 at week 24, and -44%, p < 0.01 at
week 48). There were no differences in any of the bio-
markers changes between groups during the 48-week
period. Among the inflammatory biomarkers studied, a
trend to increases from baseline was observed in hsCRP
in patients initiating abacavir/lamivudine compared with
those starting tenofovir/emtricitabine (week 4, +56.1% vs.
+13.8%; p = 0.41; week 12, +60% vs. -15.8%, p = 0.12). IL-
6 significantly increased at week 24 from baseline in
patients on abacavir (+225%, p < 0.01) but not on TDF,
although the differences were not significant between
groups. The procoagulant biomarker PAI-1 plasma levels
increased significantly from baseline at week 12 (+57%; p
= 0.017), week 24 (+72%; p = 0.008), and week 48
(+149%; p < 0.001) in the tenofovir group, whereas smal-
ler, non-significant changes were observed in the abacavir
group. Furthermore, no significant differences in PAI-1
plasma levels were found between both groups.
The endothelial biomarker sVCAM-1 declined signifi-
cantly from baseline in both treatment groups. In the
tenofovir group decreases from baseline reached statisti-
cal significance at week 4 (p = 0.004), week 12 (p <
0.001), week 24 (p < 0.001), and week 48 (p < 0.001),
and in the abacavir group at week 24 (p < 0.001) and
week 48 (p < 0.001). Decrease was significantly higher
with tenofovir at week 12 (p = 0.032). No significant
changes both within and between groups were observed
in the levels of sICAM-1.
The following significant positive correlations were
observed between HIV-1 RNA plasma levels and bio-
markers at different weeks: IL-6 levels at week 12 (r =
+0.656; p = 0.001) and VCAM-1 at week 24 (r = +0.880;
p = 0.001).
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Figure 1 Longitudinal evaluation of the percentage of change of different biomarkers from baseline by treatment groups.P e r c e n to f
change from baseline calculated as 100 · [e
mean difference from baseline -1] in which mean difference from baseline is calculated on the natural log
scale. P-value within arms reflecting whether the percent change from baseline is significantly different from 0: *P < 0.05, †P < 0.01, ‡P < 0.001.
P-value derived from the comparison in percent change from baseline between the two treatment arms (abacavir vs. tenofovir): §P = 0.032.
Comparisons were adjusted for age, sex, ART status at inclusion, viral load at baseline, lipodystrophy, Framingham score and hepatitis C virus co-
infection status.
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Our study evaluates exhaustively changes in biomarkers
of CVD during the initial weeks of therapy with abaca-
vir/lamivudine or tenofovir/emtricitabine. According to
our results, changes in inflammatory, coagulation and
endothelial function biomarkers are not different in
patients starting an antiretroviral regimen containing
abacavir or tenofovir. However, we found a dissimilar
effect of ART initiation in the plasmatic CVD risk indi-
cators. While both regimens decreased the endothelial
function marker sVCAM-1, the same trend was not
observed with the inflammatory biomarkers hsCRP and
IL-6, which remained unchanged or tended to increase
during the study period. Likewise, the procoagulation
biomarker PAI-1 increased soon after starting ART,
with significant increases from baseline in patients start-
ing tenofovir/emtricitabine.
Our results support an acute effect of the drugs on the
inflammatory, coagulation and endothelial function, with
significant changes from baseline occurring at an early
stage after initiating the drug. Another finding of the
study is that initiation of ART does not affect equally to
all mechanisms contributing to the atherosclerotic pro-
cess. The reduction of the biomarkers sVCAM-1 follow-
ing the administration of both regimens was interpreted
as an endothelium targeted effect with anti-atherogenic
activity, in agreement with previous observations in
naive patients starting ART [3,8]. Conversely, although
not different between regimes, ART initiation was also
associated with early and sustained pro-atherosclerotic
changes in the pro-coagulation, and to a lesser extent in
the inflammatory indicators measured, suggesting that
the effective control of HIV viremia is not only asso-
ciated with an overall favourable effect on CVD risk.
Abacavir induced a marginally, non significant rise in
hsCRP from baseline, in agreement with the findings of
the SMART study in patients chronically receiving aba-
cavir [2]. The observed increases in hsCRP were similar
to those found in a recent combined analysis of the
MACS & WIHS cohorts [9], which unlike the present
study also showed reduced or unchanged IL6 levels in
association with ART. Patients initiating tenofovir
experienced an early and sustained significant increase
in PAI-1, one of the main inhibitors of fibrinolysis, a
finding previously described in patients on protease
inhibitors [10]. Elevated PAI-1 plasma levels have been
associated with an increased incidence of acute coronary
syndrome [11,12].
Study limitations are the non-randomized assignment of
therapy groups and the small sample size, which might
have precluded us from finding significant differences
between groups. We do not have an explanation for the
trend to different baseline IL-6 levels between arms, which
was independent of age and sex. The high proportion of
patients with chronic liver disease associated with hepatitis
C virus coinfection might have contributed to lessen the
differences between treatment groups. However, the inves-
tigation benefits from the comprehensive panel of biomar-
kers measured, and from longitudinal sampling before and
at different time points after abacavir initiation, with mea-
surements at the early phases of exposure, and with con-
gruent changes of the markers over time in each
treatment group.
Conclusions
Changes in biomarkers of inflammation, coagulation,
and endothelial function are not different in viremic
patients starting ART with abacavir/lamivudine or teno-
fovir/emtricitabine. These changes occur in the early
phases of treatment, in particular during the first weeks
after initiating drug exposure, and include anti- and
pro-atherosclerotic effects with both drugs. Our results
reflect the complexity of phenomena accompanying
ART commencement in viremic patients, which might
suggest a closer monitoring to high CVD-risk patients
during the initial phases of ART.
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